{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:34:36Z","timestamp":1767339276358,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Ther Perspect"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40267-021-00857-8","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T11:10:27Z","timestamp":1628680227000},"page":"433-438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of the hospital pharmacist in immunocellular therapy with chimeric antigen receptor (CAR) T cells"],"prefix":"10.1007","volume":"37","author":[{"given":"Florbela","family":"Braga","sequence":"first","affiliation":[]},{"given":"Sandra","family":"Morgado","sequence":"additional","affiliation":[]},{"given":"F\u00e1tima","family":"Roque","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2112-2835","authenticated-orcid":false,"given":"Manuel","family":"Morgado","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"issue":"2","key":"857_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2019.229781","volume":"105","author":"I Yakoub-Agha","year":"2020","unstructured":"Yakoub-Agha I, Chabannon C, Bader P, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105(2):297\u2013316.","journal-title":"Haematologica"},{"key":"857_CR2","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Rivi\u00e8re I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015. https:\/\/doi.org\/10.1038\/mto.2016.15.","journal-title":"Mol Ther Oncolytics."},{"key":"857_CR3","unstructured":"European Medicines Agency. Kymriah\u00ae summary of product characteristics. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kymriah-epar-product-information_pt.pdf. Accessed 23 Sep 2020."},{"key":"857_CR4","unstructured":"European Medicines Agency. Yescarta\u00ae summary of product characteristics. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/Yescarta-epar-product-information_pt.pdf. Accessed 24 Sep 2020."},{"issue":"8","key":"857_CR5","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41409-020-0892-7","volume":"55","author":"M Mohty","year":"2020","unstructured":"Mohty M, Dulery R, Gauthier J, et al. CAR T-cell therapy for the management of refractory\/relapsed high-grade B-cell lymphoma: a practical overview. Bone Marrow Transplant. 2020;55(8):1525\u201332.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"857_CR6","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1172\/JCI129208","volume":"130","author":"MJ Frigault","year":"2020","unstructured":"Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Investig. 2020;130(4):1586\u201394.","journal-title":"J Clin Investig"},{"issue":"6","key":"857_CR7","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Investig. 2016;126(6):2123\u201338. https:\/\/doi.org\/10.1172\/JCI85309.","journal-title":"J Clin Investig"},{"key":"857_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"857_CR9","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.3747\/co.27.5283","volume":"27","author":"DA Wall","year":"2020","unstructured":"Wall DA, Krueger J. Chimeric antigen receptor T cell therapy comes to clinical practice. Curr Oncol. 2020;27(Suppl 2):S115\u201323.","journal-title":"Curr Oncol"},{"issue":"2","key":"857_CR10","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Weiss SL, Maude SL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45(2):e124\u201331. https:\/\/doi.org\/10.1097\/CCM.0000000000002053.","journal-title":"Crit Care Med"},{"issue":"1","key":"857_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","volume":"11","author":"D Porter","year":"2018","unstructured":"Porter D, Frey N, Wood PA, et al. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel [published correction appears in J Hematol Oncol. 2018 Jun 13;11(1):81]. J Hematol Oncol. 2018;11(1):35. https:\/\/doi.org\/10.1186\/s13045-018-0571-y.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"857_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"857_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamaoncol.2019.3869","volume":"6","author":"FL Locke","year":"2020","unstructured":"Locke FL, Go WY, Neelapu SS. Development and use of the anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in large B-cell lymphoma: a review. JAMA Oncol. 2020;6(2):281\u201390.","journal-title":"JAMA Oncol"},{"issue":"Suppl 3","key":"857_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.6004\/jadpro.2019.10.4.11","volume":"10","author":"S Adkins","year":"2019","unstructured":"Adkins S. CAR T-cell therapy: adverse events and management. J Adv Pract Oncol. 2019;10(Suppl 3):21\u20138. https:\/\/doi.org\/10.6004\/jadpro.2019.10.4.11.","journal-title":"J Adv Pract Oncol"},{"issue":"5","key":"857_CR15","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1177\/1078155219836480","volume":"25","author":"A Dushenkov","year":"2019","unstructured":"Dushenkov A, Jungsuwadee P. Chimeric antigen receptor T-cell therapy: foundational science and clinical knowledge for pharmacy practice. J Oncol Pharm Pract. 2019;25(5):1217\u201325.","journal-title":"J Oncol Pharm Pract"},{"key":"857_CR16","unstructured":"Herreros JMA, Hern\u00e1ndez MAC, Soler MJC, et al. Procedimiento de gesti\u00f3n de medicamentos CAR-T. Madrid: Sociedad Espa\u00f1ola de Farmacia Hospitalaria; 2019. https:\/\/gruposdetrabajo.sefh.es\/gedefo\/images\/stories\/documentos\/2019\/PROCEDIMIENTO_DE_GESTIN_DE_MEDICAMENTOS_CAR-T.pdf. Accessed 24 Aug 2020."},{"issue":"5","key":"857_CR17","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/ejhpharm-2014-000526","volume":"21","author":"European Association of Hospitalar Pharmacists","year":"2014","unstructured":"European Association of Hospitalar Pharmacists. The European statements of hospital pharmacy. Eur J Hosp Pharm. 2014;21(5):256\u20138.","journal-title":"Eur J Hosp Pharm"},{"issue":"1","key":"857_CR18","first-page":"26","volume":"44","author":"ME Moreno-Mart\u00ednez","year":"2020","unstructured":"Moreno-Mart\u00ednez ME, Vinent-Genestar J, Mu\u00f1oz-S\u00e1nchez C, et al. Hospital pharmacist\u2019s roles and responsibilities with CAR-T medicines. Farm Hosp. 2020;44(1):26\u201331.","journal-title":"Farm Hosp"},{"issue":"Suppl 2","key":"857_CR19","doi-asserted-by":"publisher","first-page":"S205","DOI":"10.1016\/S0007-4551(19)30051-7","volume":"105","author":"M Pinturaud","year":"2018","unstructured":"Pinturaud M, Vasseur M, Odou P. R\u00f4le du pharmacien hospitalier dans le circuit d\u2019une cat\u00e9gorie de M\u00e9dicament de Th\u00e9rapie Innovante: les lymphocytes T exprimant un R\u00e9cepteur Chim\u00e9rique \u00e0 l\u2019Antig\u00e8ne. Bull Cancer. 2018;105(Suppl 2):S205\u201313.","journal-title":"Bull Cancer"},{"issue":"7","key":"857_CR20","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1177\/1078155220948940","volume":"26","author":"JP Booth","year":"2020","unstructured":"Booth JP, Kusoski CL, Kennerly-Shah JM. The pharmacist\u2019s role in chimeric antigen receptor T cell therapy. J Oncol Pharm Pract. 2020;26(7):1725\u201331.","journal-title":"J Oncol Pharm Pract"},{"key":"857_CR21","doi-asserted-by":"publisher","first-page":"636068","DOI":"10.3389\/fonc.2021.636068","volume":"11","author":"MB Marzal-Alfaro","year":"2021","unstructured":"Marzal-Alfaro MB, Escudero-Vilaplana V, Revuelta-Herrero JL, et al. Chimeric antigen receptor T cell therapy management and safety: a practical tool from a multidisciplinary team perspective. Front Oncol. 2021;11:636068.","journal-title":"Front Oncol"}],"container-title":["Drugs & Therapy Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40267-021-00857-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40267-021-00857-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40267-021-00857-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,21]],"date-time":"2021-08-21T11:26:35Z","timestamp":1629545195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40267-021-00857-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["857"],"URL":"https:\/\/doi.org\/10.1007\/s40267-021-00857-8","relation":{},"ISSN":["1172-0360","1179-1977"],"issn-type":[{"type":"print","value":"1172-0360"},{"type":"electronic","value":"1179-1977"}],"subject":[],"published":{"date-parts":[[2021,8,11]]},"assertion":[{"value":"20 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No research funding was provided for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Florbela Braga, Sandra Morgado, F\u00e1tima Roque and Manuel Morgado state that they have no conflicts of interest regarding the publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"FB: Acquisition, analysis and interpretation of the data, drafting of the manuscript, and technical support. SM: Analysis and interpretation of the data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. FR: Critical revision of the manuscript for important intellectual content. MM: Concept and study design and critical revision of the manuscript for important intellectual content.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}